|
1
|
Tanaka N, Sakamoto K, Okabe H, Fujioka A,
Yamamura K, Nakagawa F, Nagase H, Yokogawa T, Oguchi K, Ishida K,
et al: Repeated oral dosing of TAS-102 confers high trifluridine
incorporation into DNA and sustained antitumor activity in mouse
models. Oncol Rep. 32:2319–2326. 2014.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Fukushima M, Suzuki N, Emura T, Yano S,
Kazuno H, Tada Y, Yamada Y and Asao T: Structure and activity of
specific inhibitors of thymidine phosphorylase to potentiate the
function of antitumor 2'-deoxyribonucleosides. Biochem Pharmacol.
59:1227–1236. 2000.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Mayer RJ, Van Cutsem E, Falcone A, Yoshino
T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero
J, Komatsu Y, et al: Randomized trial of TAS-102 for refractory
metastatic colorectal cancer. N Engl J Med. 372:1909–1919.
2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Crawford J, Dale DC and Lyman GH:
Chemotherapy-induced neutropenia: Risks, consequences, and new
directions for its management. Cancer. 100:228–237. 2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Lyman GH, Kuderer N, Greene J and Balducci
L: The economics of febrile neutropenia: Implications for the use
of colony-stimulating factors. Eur J Cancer. 34:1857–1864.
1998.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Lyman GH and Kuderer NM: Filgrastim in
patients with neutropenia: Potential effects on quality of life.
Drugs. 62 (Suppl 1):S65–S78. 2002.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Network NCC: National Comprehensive Cancer
Network guidelines. 2022.
|
|
8
|
Crawford J, Becker PS, Armitage JO,
Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I,
Griffiths EA, et al: Myeloid growth factors, version 2.2017, NCCN
clinical practice guidelines in oncology. J Natl Compr Canc Netw.
15:1520–1541. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kuboki Y, Nishina T, Shinozaki E, Yamazaki
K, Shitara K, Okamoto W, Kajiwara T, Matsumoto T, Tsushima T,
Mochizuki N, et al: TAS-102 plus bevacizumab for patients with
metastatic colorectal cancer refractory to standard therapies
(C-TASK FORCE): An investigator-initiated, open-label, single-arm,
multicentre, phase 1/2 study. Lancet Oncol. 18:1172–1181.
2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Morrison VA, Wong M, Hershman D, Campos
LT, Ding B and Malin J: Observational study of the prevalence of
febrile neutropenia in patients who received filgrastim or
pegfilgrastim associated with 3-4 week chemotherapy regimens in
community oncology practices. J Manag Care Pharm. 13:337–348.
2007.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Pinter T, Klippel Z, Cesas A, Croitoru A,
Decaestecker J, Gibbs P, Hotko Y, Jassem J, Kurteva G, Novotny J,
et al: A phase III, randomized, double-blind, placebo-controlled
trial of pegfilgrastim in patients receiving first-line
FOLFOX/bevacizumab or FOLFIRI/bevacizumab for locally advanced or
metastatic colorectal cancer: Final results of the pegfilgrastim
and anti-VEGF evaluation study (PAVES). Clin Colorectal Cancer.
16:103–114. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Schwartz LH, Litière S, de Vries E, Ford
R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J,
et al: RECIST 1.1-Update and clarification: From the RECIST
committee. Eur J Cancer. 62:132–137. 2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Institute NC: Common Terminology Criteria
for Adverse Events (CTCAE) Version 4.0. 2010.
|
|
14
|
Falcone A, Ricci S, Brunetti I, Pfanner E,
Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W,
Fanchini L, et al: Phase III trial of infusional fluorouracil,
leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with
infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as
first-line treatment for metastatic colorectal cancer: The gruppo
oncologico nord ovest. J Clin Oncol. 25:1670–1676. 2007.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Hecht JR, Pillai M, Gollard R, Heim W,
Swan F, Patel R, Dreiling L, Mo M and Malik I: A randomized,
placebo-controlled phase ii study evaluating the reduction of
neutropenia and febrile neutropenia in patients with colorectal
cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin
Colorectal Cancer. 9:95–101. 2010.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Schutz FA, Jardim DL, Je Y and Choueiri
TK: Haematologic toxicities associated with the addition of
bevacizumab in cancer patients. Eur J Cancer. 47:1161–1174.
2011.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fujii H, Matsuhashi N, Kitahora M,
Takahashi T, Hirose C, Iihara H, Yamada Y, Watanabe D, Ishihara T,
Suzuki A and Yoshida K: Bevacizumab in combination with TAS-102
improves clinical outcomes in patients with refractory metastatic
colorectal cancer: A retrospective study. Oncologist. 25:e469–e476.
2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Wildiers H and Reiser M: Relative dose
intensity of chemotherapy and its impact on outcomes in patients
with early breast cancer or aggressive lymphoma. Crit Rev Oncol
Hematol. 77:221–240. 2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Nakayama G, Tanaka C, Uehara K, Mashita N,
Hayashi N, Kobayashi D, Kanda M, Yamada S, Fujii T, Sugimoto H, et
al: The impact of dose/time modification in irinotecan- and
oxaliplatin-based chemotherapies on outcomes in metastatic
colorectal cancer. Cancer Chemother Pharmacol. 73:847–855.
2014.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Aspinall SL, Good CB, Zhao X, Cunningham
FE, Heron BB, Geraci M, Passero V, Stone RA, Smith KJ, Rogers R, et
al: Adjuvant chemotherapy for stage III colon cancer: Relative dose
intensity and survival among veterans. BMC Cancer.
15(62)2015.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kirshner JJ, Heckler CE, Janelsins MC,
Dakhil SR, Hopkins JO, Coles C and Morrow GR: Prevention of
pegfilgrastim-induced bone pain: A phase III double-blind
placebo-controlled randomized clinical trial of the university of
rochester cancer center clinical community oncology program
research base. J Clin Oncol. 30:1974–1979. 2012.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kirshner JJ, McDonald MC III, Kruter F,
Guinigundo AS, Vanni L, Maxwell CL, Reiner M, Upchurch TE, Garcia J
and Morrow PK: NOLAN: A randomized, phase 2 study to estimate the
effect of prophylactic naproxen or loratadine vs no prophylactic
treatment on bone pain in patients with early-stage breast cancer
receiving chemotherapy and pegfilgrastim. Support Care Cancer.
26:1323–1334. 2018.PubMed/NCBI View Article : Google Scholar
|
